Last reviewed · How we verify
Bevacizumab + FOLFIRI-3
Bevacizumab + FOLFIRI-3 is a Monoclonal antibody + chemotherapy combination Small molecule drug developed by AryoGen Pharmed Co.. It is currently in Phase 3 development for Metastatic colorectal cancer (Phase 3 pipeline indication). Also known as: FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil.
Bevacizumab blocks VEGF to inhibit tumor angiogenesis, while FOLFIRI-3 (fluorouracil, leucovorin, and irinotecan) provides chemotherapy-induced DNA damage and cell death.
Bevacizumab blocks VEGF to inhibit tumor angiogenesis, while FOLFIRI-3 (fluorouracil, leucovorin, and irinotecan) provides chemotherapy-induced DNA damage and cell death. Used for Metastatic colorectal cancer (Phase 3 pipeline indication).
At a glance
| Generic name | Bevacizumab + FOLFIRI-3 |
|---|---|
| Also known as | FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil |
| Sponsor | AryoGen Pharmed Co. |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | VEGF (bevacizumab); Thymidylate synthase and topoisomerase I (FOLFIRI-3) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. FOLFIRI-3 is a combination chemotherapy regimen where fluorouracil and leucovorin inhibit thymidylate synthase, and irinotecan inhibits topoisomerase I, together inducing apoptosis in rapidly dividing cancer cells. The combination leverages anti-angiogenic and cytotoxic mechanisms for enhanced efficacy.
Approved indications
- Metastatic colorectal cancer (Phase 3 pipeline indication)
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Hypertension
- Proteinuria
- Bleeding
- Fatigue
Key clinical trials
- Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer (PHASE3)
- Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
- Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab + FOLFIRI-3 CI brief — competitive landscape report
- Bevacizumab + FOLFIRI-3 updates RSS · CI watch RSS
- AryoGen Pharmed Co. portfolio CI
Frequently asked questions about Bevacizumab + FOLFIRI-3
What is Bevacizumab + FOLFIRI-3?
How does Bevacizumab + FOLFIRI-3 work?
What is Bevacizumab + FOLFIRI-3 used for?
Who makes Bevacizumab + FOLFIRI-3?
Is Bevacizumab + FOLFIRI-3 also known as anything else?
What drug class is Bevacizumab + FOLFIRI-3 in?
What development phase is Bevacizumab + FOLFIRI-3 in?
What are the side effects of Bevacizumab + FOLFIRI-3?
What does Bevacizumab + FOLFIRI-3 target?
Related
- Drug class: All Monoclonal antibody + chemotherapy combination drugs
- Target: All drugs targeting VEGF (bevacizumab); Thymidylate synthase and topoisomerase I (FOLFIRI-3)
- Manufacturer: AryoGen Pharmed Co. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer (Phase 3 pipeline indication)
- Also known as: FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil
- Compare: Bevacizumab + FOLFIRI-3 vs similar drugs
- Pricing: Bevacizumab + FOLFIRI-3 cost, discount & access